CD80 and neoplasm: By exploring pDC diversity, we observed an increased frequency of P3-pDCs (CD80+PD-L1−) in the blood of melanoma patients compared to healthy volunteers, together with their accumulation within the tumor, which was linked to a bad clinical outcome [28].